(NASDAQ: ALKS) Alkermes's forecast annual revenue growth rate of -2.79% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Alkermes's revenue in 2025 is $1,513,770,000.On average, 8 Wall Street analysts forecast ALKS's revenue for 2025 to be $227,179,388,405, with the lowest ALKS revenue forecast at $224,687,565,087, and the highest ALKS revenue forecast at $231,191,601,570. On average, 8 Wall Street analysts forecast ALKS's revenue for 2026 to be $230,626,484,866, with the lowest ALKS revenue forecast at $217,357,208,265, and the highest ALKS revenue forecast at $250,485,051,915.
In 2027, ALKS is forecast to generate $228,206,063,805 in revenue, with the lowest revenue forecast at $220,068,350,292 and the highest revenue forecast at $246,857,223,645.